Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Credit NIAID-RML
Highlighted Sections
Clinical Management Summary
This section contains figures with the Panel’s recommendations for the therapeutic management of adults with COVID-19 and children with MIS-C.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
SARS-CoV-2 viral rebound and the recurrence of COVID-19 symptoms have been reported in patients who completed a 5-day course of ritonavir-boosted nirmatrelvir.
Prioritization of Therapeutics
The Panel emphasizes that this prioritization guidance should be used only when logistical or supply constraints limit the availability of therapies.
Paxlovid Drug-Drug Interactions
This section provides resources for identifying and managing interactions between ritonavir-boosted nirmatrelvir and concomitant medications.
Anti-SARS-CoV-2 Monoclonal Antibodies
This section now includes information on the role of bebtelovimab in the treatment of certain nonhospitalized patients with mild to moderate COVID-19.
Therapeutic Management of Nonhospitalized Adults
The Panel no longer recommends using sotrovimab to treat COVID-19, and the recommendations and rationale for using sotrovimab have been removed from this section.
Clinical Management Summary
This section contains figures with the Panel’s recommendations for the therapeutic management of adults with COVID-19 and children with MIS-C.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
SARS-CoV-2 viral rebound and the recurrence of COVID-19 symptoms have been reported in patients who completed a 5-day course of ritonavir-boosted nirmatrelvir.
Prioritization of Therapeutics
The Panel emphasizes that this prioritization guidance should be used only when logistical or supply constraints limit the availability of therapies.
Paxlovid Drug-Drug Interactions
This section provides resources for identifying and managing interactions between ritonavir-boosted nirmatrelvir and concomitant medications.
Anti-SARS-CoV-2 Monoclonal Antibodies
This section now includes information on the role of bebtelovimab in the treatment of certain nonhospitalized patients with mild to moderate COVID-19.
Therapeutic Management of Nonhospitalized Adults
The Panel no longer recommends using sotrovimab to treat COVID-19, and the recommendations and rationale for using sotrovimab have been removed from this section.
Clinical Management Summary
This section contains figures with the Panel’s recommendations for the therapeutic management of adults with COVID-19 and children with MIS-C.
Ritonavir-Boosted Nirmatrelvir (Paxlovid)
SARS-CoV-2 viral rebound and the recurrence of COVID-19 symptoms have been reported in patients who completed a 5-day course of ritonavir-boosted nirmatrelvir.
Prioritization of Therapeutics
The Panel emphasizes that this prioritization guidance should be used only when logistical or supply constraints limit the availability of therapies.
Paxlovid Drug-Drug Interactions
This section provides resources for identifying and managing interactions between ritonavir-boosted nirmatrelvir and concomitant medications.
Anti-SARS-CoV-2 Monoclonal Antibodies
This section now includes information on the role of bebtelovimab in the treatment of certain nonhospitalized patients with mild to moderate COVID-19.
Therapeutic Management of Nonhospitalized Adults
The Panel no longer recommends using sotrovimab to treat COVID-19, and the recommendations and rationale for using sotrovimab have been removed from this section.